SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
FATE reported Third Quarter 2026 results. The price and volatility reaction is pending.
FATEearnings

Earnings reactions, page 6

Fate Therapeutics, Inc. (FATE) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss was $30.7 million, or $(0.25) per share, for the third quarter of 2026.
  • Total operating expenses were $32.2 million for the third quarter of 2026.
  • Research and development expenses were $24.2 million for the third quarter of 2026.
  • General and administrative expenses were $8.0 million for the third quarter of 2026.
  • Cash, cash equivalents, and investments as of September 30, 2026, were $139.1 million.

Guidance

  • Cash runway expected to mid-2028, including the $139.1 million in cash, cash equivalents, and investments and the $15.0 million CIRM grant.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →